The integrin ␣ 9  1 mediates cell adhesion to tenascin-C and VCAM-1 by binding to sequences distinct from the common integrin-recognition sequence, arginine-glycine-aspartic acid (RGD). A thrombin-cleaved NH 2 -terminal fragment of osteopontin containing the RGD sequence has recently been shown to also be a ligand for ␣ 9  1 . In this report, we used site-directed mutagenesis and synthetic peptides to identify the ␣ 9  1 recognition sequence in osteopontin. ␣ 9 -transfected SW480, Chinese hamster ovary, and L-cells adhered to a recombinant NH 2 -terminal osteopontin fragment in which the RGD site was mutated to RAA (nOPN-RAA). Adhesion was completely inhibited by anti-␣ 9 monoclonal antibody Y9A2, indicating the presence of a non-RGD ␣ 9  1 recognition sequence within this fragment. Alanine substitution mutagenesis of 13 additional conserved negatively charged amino acid residues in this fragment had no effect on ␣ 9  1 -mediated adhesion, but adhesion was dramatically inhibited by either alanine substitution or deletion of tyrosine 165. A synthetic peptide, SVVYGLR, corresponding to the sequence surrounding Tyr 165 , blocked ␣ 9  1 -mediated adhesion to nOPN-RAA and exposed a ligand-binding-dependent epitope on the integrin  1 subunit on ␣ 9 -transfected, but not on mocktransfected cells. These results demonstrate that the linear sequence SVVYGLR directly binds to ␣ 9  1 and is responsible for ␣ 9  1 -mediated cell adhesion to the NH 2 -terminal fragment of osteopontin.Integrins are cell surface heterodimeric receptors that mediate cell-cell and cell-extracellular matrix adhesion (1, 2). Upon ligation by a wide variety of ligands, integrins can initiate signaling cascades that regulate cell growth, cell death, migration, polarization, and tissue remodeling (3). Integrins recognize a surprisingly large number of functionally diverse proteins as ligands, and the list of known integrin ligands continues to grow. New integrin ligands have been identified, and drugs targeting integrins have been developed as a consequence of the description of short linear amino acid sequences that directly bind to integrins. For example, the integrins, and ␣ v  8 bind to sequences containing the tri-peptide sequence Arg-Gly-Asp (RGD). Several new and biologically important integrin ligands have been identified based on the presence of this sequence (4, 5). Drugs modeled on the structure of the RGD sequence are being used or tested to inhibit integrin function for treatment of thrombosis, inflammation, atherosclerosis, osteoporosis, and cancer (5). The RGD sequence has also been exploited to target cell surface integrins to enhance gene delivery (6). We have previously identified the recognition sequence for the integrin ␣ 9  1 in tenascin-C and found that this sequence did not include RGD, but was homologous to the ␣ 4  1 recognition sequence in the inducible endothelial adhesion molecule VCAM-1 (7). This finding led to our identification of ␣ 9  1 as a receptor for VCAM-1 (8).Osteopontin is a phosphorylated acidic gly...